J&J softens FDA's Invokana blow with positive kidney results by Carly Helfand Tuesday, July 17, 2018 J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.
Jardiance cuts kidney disease progression in CV outcomes test by Eric Sagonowsky Monday, June 25, 2018 In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.
J&J's Invokana, rivals cut hospitalizations in real-world study by Eric Sagonowsky Monday, June 25, 2018 Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.
Novo's oral semaglutide bests Lilly and BI's Jardiance in phase 3 by Eric Sagonowsky Wednesday, May 30, 2018 In a phase 3 study, Novo said oral semaglutide helped diabetes patients manage their blood sugar levels better than Jardiance.
Lilly’s strong Q1 cushions FDA thumbs-down on 4-mg baricitinib by Arlene Weintraub Tuesday, April 24, 2018 Lilly analysts worry growth could suffer if it doesn't win a nod for both baricitinib doses—and an FDA panel shot down one of them Monday.
With jump to CVS, ex-Lilly exec Rice joins Witty in payer industry by Eric Sagonowsky Wednesday, March 21, 2018 Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.
AZ touts SGLT2 benefits with latest batch of real-world data by Carly Helfand Sunday, March 11, 2018 When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.
Lilly, BI add two new Jardiance heart failure studies by Carly Helfand Wednesday, March 7, 2018 Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.
Novo shifts Victoza ad message with new CV spots by Beth Snyder Bulik Thursday, March 8, 2018 Novo Nordisk's newest Victoza campaign doubles down on its approved trifecta of preventative indications for heart attack, stroke and CV death.
